FDA safety reports link stimulant drinks to sharper heart-event signals
Federal adverse event reports are drawing new attention to a familiar product with a less familiar risk profile. A preliminary analysis presented at the American Heart Association Scientific Sessions 2026 found that energy drinks and dietary supplements containing caffeine or other stimulants were far more likely to be associated with reports of serious cardiovascular events than products without those ingredients.
The pattern was strongest for cardiac arrest, heart attack, ventricular arrhythmias, palpitations, elevated heart rate, chest pain, and fainting. Those signals do not prove cause and effect, but they do place stimulant-heavy beverages and supplements squarely in the path of cardiovascular concern, especially for younger adults who may use them for energy, exercise, or alertness.
The age distribution stood out. Adults ages 18 to 34 accounted for about 45% of reports involving stimulant-containing products and cardiovascular events. In a population where serious cardiac events are less common than in older adults, that share invites a hard look at consumption patterns, product stacking, and undiagnosed disease.
What the FDA database showed across 28,345 reports
Researchers reviewed 28,345 reports of possible adverse events recorded in a U.S. Food and Drug Administration safety database from 2017 through 2025. Of these, 854 involved energy drinks or dietary supplements containing caffeine or other stimulants. The comparison group included 27,491 reports tied to products without those ingredients, such as soft drinks, protein bars, meal replacement shakes, smoothies, and vitamins.
The contrast was striking. Reports involving stimulant-containing products were about 11 times more likely to mention cardiac arrest and about 4.5 times more likely to mention heart attack. They were four times more likely to mention ventricular arrhythmias or heart palpitations, nearly three times more likely to mention an elevated heart rate, 2.71 times more likely to mention chest pain, and about twice as likely to mention fainting.
One sentence captures the central limitation: these were differences in reporting frequency, not measured risks in a defined exposed population.
That distinction matters because FDA safety reports are designed to detect potential signals, not to establish incidence, causality, or absolute risk. The database cannot show how many people consumed these products without trouble, nor can it separate out dose, duration, timing, or co-exposures with enough precision to quantify harm.
Why stimulants can stress the heart
The biological rationale is straightforward. Caffeine increases sympathetic nervous system activity, which can raise heart rate, elevate blood pressure, and increase myocardial workload. In a healthy adult, that may be transient and modest at typical doses. In a person who is sensitive to caffeine, already hypertensive, prone to arrhythmia, or using multiple stimulant sources, the same physiologic push can become destabilizing.
Many energy drinks do not rely on caffeine alone. They may also contain ingredients such as guarana and taurine, which can further amplify cardiovascular stimulation and stress hormone release. Pre-workout supplements may contain similar combinations, sometimes at concentrations that are difficult for consumers to interpret when labels list ingredient names rather than a simple caffeine total.
Chen, a board-certified interventional cardiologist who was not involved in the study, described the concern plainly: caffeine can increase blood pressure and heart rate, and other ingredients may add to the cardiovascular load. He also noted the risk of abnormal heart rhythms, particularly in people with underlying cardiovascular conditions. His comments align with the physiology seen at the bedside, where palpitations, lightheadedness, chest discomfort, and fainting can follow excessive stimulant exposure.
Young adults and the habits that may raise exposure
The heavy representation of adults ages 18 to 34 does not automatically mean this age group faces the highest biological vulnerability. It may instead reflect how these products are used. Younger adults may reach for energy drinks before workouts, during long shifts, while studying, or in combination with alcohol and other caffeinated products. Some may also underestimate total daily caffeine intake because stimulants come from several sources at once.
A practical problem sits underneath the numbers: consumers often do not track caffeine the way they would track a prescription dose. Coffee, tea, energy drinks, pre-workout powders, and stimulant supplements can all land in the same day, and serving sizes are not always intuitive. A single can may contain enough caffeine to matter, and more than one product can push total intake well beyond what a person assumes is safe.
Undiagnosed heart disease may also be part of the story. A young adult with latent arrhythmia susceptibility, hypertension, or another unrecognized condition can appear healthy until a stimulant load provokes symptoms. In that setting, a product marketed for alertness or performance may become the trigger that reveals a hidden problem.
What this means for clinicians and consumers
The study does not justify saying energy drinks cause heart attacks or cardiac arrest. It does justify closer questioning when a younger patient presents with palpitations, chest pain, dyspnea, fainting, or unexplained tachycardia. Stimulant use belongs in the history alongside medications, recreational substances, exercise, and sleep deprivation.
Clinicians should ask specifically about energy drinks and pre-workout supplements, not just coffee. Patients often do not recognize those products as part of their stimulant burden. That gap can delay diagnosis, especially when the symptoms are episodic and resolve before medical evaluation.
For consumers, the most defensible precaution is to treat total stimulant exposure as a cumulative daily issue rather than a single-drink issue. Product labels should be checked carefully, especially when multiple caffeinated products are used on the same day. People with hypertension, arrhythmias, or prior cardiac symptoms may need to avoid these products altogether or limit them far more strictly than the average healthy adult.
The study’s value lies in the warning signal, not the verdict. It adds to a growing body of concern around caffeine- and stimulant-containing products, but the database design cannot isolate which ingredients, doses, or combinations are driving the reports. Until prospective studies or better exposure data answer those questions, the safest clinical reading is simple: stimulant-heavy beverages and supplements deserve caution, particularly in young adults with symptoms or hidden cardiovascular risk.